WO2002044192A1 - Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions - Google Patents

Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions Download PDF

Info

Publication number
WO2002044192A1
WO2002044192A1 PCT/JP2001/010115 JP0110115W WO0244192A1 WO 2002044192 A1 WO2002044192 A1 WO 2002044192A1 JP 0110115 W JP0110115 W JP 0110115W WO 0244192 A1 WO0244192 A1 WO 0244192A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
substituted lower
intermediates
production
same
Prior art date
Application number
PCT/JP2001/010115
Other languages
English (en)
French (fr)
Inventor
Hideki Fujikura
Toshihiro Nishimura
Nobuhiko Fushimi
Kazuya Tatani
Norihiko Kikuchi
Kenji Katsuno
Masayuki Isaji
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co., Ltd. filed Critical Kissei Pharmaceutical Co., Ltd.
Priority to EP01998555A priority Critical patent/EP1344780A4/en
Priority to US10/432,905 priority patent/US7053060B2/en
Priority to CA002429833A priority patent/CA2429833A1/en
Priority to AU2002223127A priority patent/AU2002223127A1/en
Priority to JP2002546562A priority patent/JP4212891B2/ja
Publication of WO2002044192A1 publication Critical patent/WO2002044192A1/ja
Priority to US10/978,413 priority patent/US7129381B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
PCT/JP2001/010115 2000-11-30 2001-11-20 Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions WO2002044192A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01998555A EP1344780A4 (en) 2000-11-30 2001-11-20 GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
US10/432,905 US7053060B2 (en) 2000-11-30 2001-11-20 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
CA002429833A CA2429833A1 (en) 2000-11-30 2001-11-20 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
AU2002223127A AU2002223127A1 (en) 2000-11-30 2001-11-20 Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
JP2002546562A JP4212891B2 (ja) 2000-11-30 2001-11-20 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物およびその製造中間体
US10/978,413 US7129381B2 (en) 2000-11-30 2004-11-02 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000366192 2000-11-30
JP2000-366192 2000-11-30
JP2000-380482 2000-12-14
JP2000380482 2000-12-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10432905 A-371-Of-International 2001-11-20
US10/978,413 Division US7129381B2 (en) 2000-11-30 2004-11-02 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof

Publications (1)

Publication Number Publication Date
WO2002044192A1 true WO2002044192A1 (fr) 2002-06-06

Family

ID=26605024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010115 WO2002044192A1 (fr) 2000-11-30 2001-11-20 Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions

Country Status (9)

Country Link
US (3) US7053060B2 (ja)
EP (1) EP1344780A4 (ja)
JP (1) JP4212891B2 (ja)
AR (1) AR034280A1 (ja)
AU (1) AU2002223127A1 (ja)
CA (1) CA2429833A1 (ja)
PE (1) PE20020573A1 (ja)
TW (1) TWI290556B (ja)
WO (1) WO2002044192A1 (ja)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367060A1 (en) * 2001-02-14 2003-12-03 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
WO2004050122A1 (ja) * 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. 高血糖症に起因する疾患の予防又は治療剤
JP2004196788A (ja) * 2002-12-04 2004-07-15 Kissei Pharmaceut Co Ltd ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
WO2004099230A1 (en) * 2003-05-12 2004-11-18 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
JP2006510643A (ja) * 2002-12-12 2006-03-30 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新しい芳香族フルオログリコシド誘導体、該化合物を含有する医薬品、およびその使用
JP2006510644A (ja) * 2002-12-12 2006-03-30 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新しい複素環フルオログリコシド誘導体、該化合物を含有する医薬品、およびその使用
JP2006232825A (ja) * 2005-01-31 2006-09-07 Tanabe Seiyaku Co Ltd 医薬組成物
JP2007518682A (ja) * 2003-08-01 2007-07-12 田辺製薬株式会社 新規化合物
WO2007128761A2 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Verwendungen von dpp iv inhibitoren
WO2007147478A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3 -amino- imidazo [1, 2-a] pyridinderivate als sglt inhibitoren
WO2008016132A1 (en) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Benzyl phenyl glucopyranoside derivative
JPWO2005095429A1 (ja) * 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 フェノール誘導体、それを含有する医薬組成物及びその医薬用途
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
WO2009096503A1 (ja) * 2008-01-31 2009-08-06 Daiichi Sankyo Company, Limited ベンジルフェニルグルコピラノシド誘導体
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
US7767651B2 (en) 2005-01-28 2010-08-03 Chugai Seiyaku Kabushiki Kaisha Spiroketal derivatives and use thereof as diabetic medicine
WO2011039338A2 (en) 2009-10-02 2011-04-07 Sanofi-Aventis Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
WO2011051864A1 (en) 2009-11-02 2011-05-05 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2774619A1 (de) 2013-03-04 2014-09-10 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
US9573959B2 (en) 2013-03-14 2017-02-21 Msd International Gmbh Methods for preparing SGLT2 inhibitors
WO2023222144A1 (zh) * 2022-05-18 2023-11-23 上海科利生物医药有限公司 一类硫代糖苷列净类似物及其制备方法和应用

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
EP1344780A4 (en) * 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
US7371732B2 (en) * 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
CA2557801C (en) 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006064033A2 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ES2334940T3 (es) 2005-02-23 2010-03-17 Boehringer Ingelheim International Gmbh Derivados de ((hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo y uso de los mismos como inhibidores del cotransportador 2 de glucosa dependiente de sodio (sglt2).
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
ATE468347T1 (de) 2005-07-27 2010-06-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)- benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters (sglt)
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
US8507450B2 (en) 2005-09-08 2013-08-13 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
EP1989191B1 (en) 2006-02-15 2011-07-20 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
WO2009014970A1 (en) 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
RS52236B (en) * 2008-08-28 2012-10-31 Pfizer Inc. DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
MX2012002942A (es) 2009-09-30 2012-04-11 Boehringer Ingelheim Int Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
KR101813025B1 (ko) 2009-09-30 2017-12-28 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실­치환된 벤질­벤젠 유도체의 제조방법
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
US20140088027A1 (en) 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
MX2013014135A (es) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2981269T3 (da) 2013-04-04 2023-10-23 Boehringer Ingelheim Vetmedica Gmbh Behandling af stofskifteforstyrrelser hos hestedyr
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2906115T3 (es) 2013-04-18 2022-04-13 Boehringer Ingelheim Int Composición farmacéutica, métodos de tratamiento y usos de la misma
KR20240017116A (ko) 2013-12-17 2024-02-06 베링거잉겔하임베트메디카게엠베하 고양이과 동물에서 대사 장애의 치료
ES2951127T3 (es) 2014-01-23 2023-10-18 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
JP6793640B2 (ja) 2014-06-24 2020-12-02 ザ ユニバーシティ オブ カンザス Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド
AU2017344882A1 (en) 2016-10-19 2019-03-28 Boehringer Ingelheim International Gmbh Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2019271126A1 (en) 2018-05-14 2020-12-10 Reata Pharmaceuticals, Inc. Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
US11759474B2 (en) 2019-11-28 2023-09-19 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
KR20240040106A (ko) 2021-07-28 2024-03-27 베링거잉겔하임베트메디카게엠베하 비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物，特别是犬科动物中预防和/或治疗心脏疾病的用途
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232946A (en) * 1987-06-04 1993-08-03 Dr. Karl Thomae Gmbh Phenylethanolamines, their use as pharmaceuticals and as performance enhancers in animals
EP0598359A1 (en) * 1992-11-12 1994-05-25 Tanabe Seiyaku Co., Ltd. Hypoglycemic dihydrochalcone derivatives
JPH09241128A (ja) * 1996-03-01 1997-09-16 Nippon Paint Co Ltd チロシナーゼ活性阻害剤
WO2001074834A1 (en) * 2000-03-30 2001-10-11 Bristol-Myers Squibb Company O-aryl glucoside sglt2 inhibitors and method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549476B1 (fr) 1983-07-20 1986-04-25 Rech Ind Benzyl-phenyl-osides, procede de preparation et utilisation en therapeutique
DE3740441A1 (de) * 1987-11-28 1989-06-08 Roehm Gmbh Pharmazeutisch wirksame pteridinderivate
JP3274170B2 (ja) * 1992-04-16 2002-04-15 三井化学株式会社 可逆性熱変色材料
US5731292A (en) 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CZ303372B6 (cs) * 1999-08-31 2012-08-22 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát a farmaceutická kompozice s jeho obsahem a benzylpyrazolový meziprodukt
KR100660738B1 (ko) * 2000-03-17 2006-12-22 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실록시 벤질벤젠 유도체, 그것을 함유하는의약조성물 및 그 제조중간체
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
IL155071A0 (en) * 2000-09-29 2003-10-31 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
EP1344780A4 (en) * 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
HU228915B1 (en) * 2000-12-28 2013-06-28 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
DE60230591D1 (de) * 2001-02-26 2009-02-12 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
JP4147111B2 (ja) * 2001-02-27 2008-09-10 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体およびその医薬用途
CA2448741C (en) * 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232946A (en) * 1987-06-04 1993-08-03 Dr. Karl Thomae Gmbh Phenylethanolamines, their use as pharmaceuticals and as performance enhancers in animals
EP0598359A1 (en) * 1992-11-12 1994-05-25 Tanabe Seiyaku Co., Ltd. Hypoglycemic dihydrochalcone derivatives
JPH09241128A (ja) * 1996-03-01 1997-09-16 Nippon Paint Co Ltd チロシナーゼ活性阻害剤
WO2001074834A1 (en) * 2000-03-30 2001-10-11 Bristol-Myers Squibb Company O-aryl glucoside sglt2 inhibitors and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1344780A4 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367060A1 (en) * 2001-02-14 2003-12-03 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1367060A4 (en) * 2001-02-14 2004-04-14 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
US7541341B2 (en) 2001-02-14 2009-06-02 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
WO2004050122A1 (ja) * 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. 高血糖症に起因する疾患の予防又は治療剤
JP2004196788A (ja) * 2002-12-04 2004-07-15 Kissei Pharmaceut Co Ltd ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
JP4651934B2 (ja) * 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
US7288528B2 (en) 2002-12-12 2007-10-30 Sanofi-Aventis Deutschland Gmbh Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
JP2006510643A (ja) * 2002-12-12 2006-03-30 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新しい芳香族フルオログリコシド誘導体、該化合物を含有する医薬品、およびその使用
JP4806192B2 (ja) * 2002-12-12 2011-11-02 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新しい芳香族フルオログリコシド誘導体、該化合物を含有する医薬品、およびその使用
JP2006510644A (ja) * 2002-12-12 2006-03-30 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新しい複素環フルオログリコシド誘導体、該化合物を含有する医薬品、およびその使用
JP4806193B2 (ja) * 2002-12-12 2011-11-02 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新しい複素環フルオログリコシド誘導体、該化合物を含有する医薬品、およびその使用
WO2004099230A1 (en) * 2003-05-12 2004-11-18 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
JP2007518682A (ja) * 2003-08-01 2007-07-12 田辺製薬株式会社 新規化合物
JP4717811B2 (ja) * 2003-08-01 2011-07-06 田辺三菱製薬株式会社 新規化合物
JPWO2005095429A1 (ja) * 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 フェノール誘導体、それを含有する医薬組成物及びその医薬用途
US7767651B2 (en) 2005-01-28 2010-08-03 Chugai Seiyaku Kabushiki Kaisha Spiroketal derivatives and use thereof as diabetic medicine
JP2006232825A (ja) * 2005-01-31 2006-09-07 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007128761A2 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Verwendungen von dpp iv inhibitoren
EP2351568A2 (de) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Verwendungen von dpp iv Inhibitoren
WO2007147478A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3 -amino- imidazo [1, 2-a] pyridinderivate als sglt inhibitoren
WO2008016132A1 (en) 2006-08-04 2008-02-07 Daiichi Sankyo Company, Limited Benzyl phenyl glucopyranoside derivative
EP2325182A1 (en) 2006-12-06 2011-05-25 Glaxosmithkline LLC Bicyclic compounds and use as antidiabetics
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2009049731A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo [ 1, 2 -a] pyrimidinderivate zur behandlung von erkrankungen wie diabetes
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
WO2009096503A1 (ja) * 2008-01-31 2009-08-06 Daiichi Sankyo Company, Limited ベンジルフェニルグルコピラノシド誘導体
WO2009124638A1 (de) 2008-04-07 2009-10-15 Merck Patent Gmbh Glucopyranosidderivate
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
WO2011039338A2 (en) 2009-10-02 2011-04-07 Sanofi-Aventis Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
WO2011051864A1 (en) 2009-11-02 2011-05-05 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2774619A1 (de) 2013-03-04 2014-09-10 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US9573959B2 (en) 2013-03-14 2017-02-21 Msd International Gmbh Methods for preparing SGLT2 inhibitors
EP3466431A1 (en) 2013-03-14 2019-04-10 MSD International GmbH Crystalline forms and methods for preparing sglt2 inhibitors
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
WO2015173383A1 (de) 2014-05-16 2015-11-19 Bioactive Food Gmbh Kombination von biologisch aktiven substanzen zur behandlung von hyperglykämischen erkrankungen
WO2023222144A1 (zh) * 2022-05-18 2023-11-23 上海科利生物医药有限公司 一类硫代糖苷列净类似物及其制备方法和应用

Also Published As

Publication number Publication date
US20050059614A1 (en) 2005-03-17
JP4212891B2 (ja) 2009-01-21
CA2429833A1 (en) 2002-06-06
EP1344780A4 (en) 2004-01-28
US7129381B2 (en) 2006-10-31
AR034280A1 (es) 2004-02-18
US20040063170A1 (en) 2004-04-01
JPWO2002044192A1 (ja) 2004-04-02
PE20020573A1 (es) 2002-07-31
AU2002223127A1 (en) 2002-06-11
TWI290556B (en) 2007-12-01
US20050113315A1 (en) 2005-05-26
US7053060B2 (en) 2006-05-30
EP1344780A1 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
WO2002044192A1 (fr) Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
WO2003011880A1 (fr) Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
BG106451A (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
WO2002028872A1 (fr) Derives de glucopyranosiloxybenzylbenzene et compositions therapeutiques contenant ces composes
HK1082743A1 (en) Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
MY136581A (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
TW200637839A (en) 1-thio-d-glucitol derivatives
HK1055973A1 (en) Glucopyranosyloxy benzylbenzene derivatives, medicinal composition containing the same and intermediates for the preparation of the derivatives.
AU2003258621A1 (en) Novel purine derivatives, production and use thereof as medicaments
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
EP1637539A4 (en) PYRAZOL DERIVATIVE MEDICAMENT COMPOSITION CONTAINING THEREOF AND INTERMEDIATE PRODUCT FOR THE PRODUCTION THEREOF
WO2005080345A3 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
EP1550668A4 (en) PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION COMPRISING THE DERIVATIVE, MEDICINAL USE THEREOF, AND INTERMEDIATE ENTERING THE PRODUCTION THEREOF
NO20063860L (no) 7-fenylamino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav samt deres anvendelse som legemidler
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
WO2004065360A3 (en) Piperazine derivatives and their use as synthesis intermediates
WO2003016269A1 (en) 5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
UA91531C2 (en) 1-thio-d-glucitol derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002546562

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2429833

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001998555

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001998555

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10432905

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642